OMEROS CORP Increase (Decrease) in Accounts Payable and Other Operating Liabilities
OMEROS CORP (OMER) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $14.64 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2022-03-01
- OMEROS CORP increase (decrease) in accounts payable and other operating liabilities for fiscal 2021 was $14.64M.
- OMEROS CORP increase (decrease) in accounts payable and other operating liabilities for fiscal 2020 was -$19.74M, a 248.58% decline from fiscal 2019.
- OMEROS CORP increase (decrease) in accounts payable and other operating liabilities for fiscal 2019 was $13.28M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|
| 2021-12-31 | $14.64M 10-K · filed 2022-03-01 |
| 2020-12-31 | -$19.74M 10-K · filed 2022-03-01 |
| 2019-12-31 | $13.28M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |